IP Library Granted Patent US 9,650,610
Granted Patent B2
US 9,650,610 · App. 14/455,059 · Granted May 16, 2017

In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells

Inventor: Alan D. Agulnick (San Diego, CA)
Assignee: ViaCyte, Inc.
C12N5/0676A61K35/39A61K35/545C12N5/0678C12N2500/25C12N2501/115C12N2501/117C12N2501/119C12N2501/15C12N2501/155C12N2501/16C12N2501/195C12N2501/385C12N2501/415C12N2501/727C12N2501/998C12N2501/999C12N2506/02C12N2506/22C12N2506/45C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,650,610
App. No.
14/455,059
Granted
May 16, 2017
Kind
B2
Abstract

A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.

Claims (26)

1. An in vitro cell culture comprising:

human cells, wherein at least 10% of said human cells are immature beta cells that co-express INS and NKX6.1; and

an effective amount of Y-27632 to promote survival of the immature beta cells in the cell culture.

2. The cell culture of claim 1 , wherein the cell culture is in a semipermeable encapsulation device.

3. The cell culture of claim 1 , wherein said human immature beta cells do not substantially express NGN3.

4. A cryopreserved in vitro cell culture comprising:

human cells, wherein the human cells comprise unipotent human immature beta cell suspension aggregates and wherein at least 10% of cells in the aggregates are human immature beta cells that co-express INS and NKX6.1, and

a cryopreservation agent.

5. The cell culture of claim 4 , wherein the unipotent human immature beta cell suspension aggregates are in a semipermeable encapsulation device.

6. The cell culture of claim 4 , wherein the suspension aggregates are about 50 to 200 microns in size.

7. A cryopreserved in vitro cell culture comprising:

human cells, wherein at least 10% of said human cells are immature beta cells that co-express INS and NKX6.1; and

a cryopreservation agent.

8. The cell culture of claim 7 , wherein said human immature beta cells do not substantially express NGN3.

9. The cell culture of claim 7 , wherein the immature beta cells are in a semipermeable encapsulation device.

10. The cell culture of claim 7 , wherein the immature beta cells are in a perforated encapsulation device.

11. The cell culture of claim 7 , wherein said human immature beta cells further co-expresses pancreatic-duodenal homeobox factor-1 (PDX1).

12. The cell culture of claim 7 , wherein said human immature beta cells are capable of maturing to a mature beta cells.

13. The cell culture of claim 7 , wherein said human immature beta cells further expresses MAFB.

14. The cell culture of claim 7 , further comprising Chromogranin A (CHGA)-negative cells.

15. The cell culture of claim 7 , further comprising a compound selected from the group consisting of bone morphogenetic protein, sonic hedgehog, platelet-derived growth factor, a member of the FGF superfamily, retinoic acid, retinoic acid analogs, insulin-like growth factor, a vitamin B3 derivative, and Nicotinamide.

16. The cell culture of claim 7 , further comprising a matrix.

17. A cryopreserved in vitro cell culture comprising:

human cells, wherein at least 50% of said human cells are immature beta cells that co-express INS and NKX6.1; and

a cryopreservation agent.

18. The cell culture of claim 17 , wherein the immature beta cells are in a semipermeable encapsulation device.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2019
From: D'AMOUR, KEVIN
To: VIACYTE, INC.
Reel/Frame 049038/0399 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2015
From: AGULNICK, ALAN D.
To: VIACYTE, INC.
Reel/Frame 035780/0828 →
Continuity (3)
Continuation 14106330 · Dec 13, 2013
Provisional Application 61781005 · Mar 14, 2013
Related Publication 20150017135A1 · Jan 15, 2015